ARCHIVES

In Brief: David Feigal To Head FDA’s Antiviral Division; ODAC To Discuss Melphalan, Amifostine NDAs

This article is from The Cancer Letter archive.

Vol. 18 No. 03 | January 17, 1992

Download PDF Visit The Full Archive

Related Articles

Predicant, Correlogic executives contradict scientists’ claim that firms didn’t appear to compete.

June 25, 2004

NIH Selects 16 Clinical Centers for Women’s Health Initiative

April 9, 1993

In Brief: Calabresi Named To President’s Cancer Panel; Mays Leaves NCI Technology Office For IVAX

May 5, 1995

Prime Contract Subcontract Opportunities

January 24, 1975

XGEVA not Inferior to Zometa In 1,776-Patient Phase III Study

March 25, 2011

In Brief: Lawyers Halt Reference Chemical Distribution To Grantees, Threaten To Stop Viruses, Animals

September 2, 1977